XGene Pharmaceutical

Coming – December 2

A Phase 3 Ready, Non-Opioid Solution For Acute Pain

Date and Time

December 2

–

12:00 PM EST/ 9:00 AM PST

Details will be provided upon RSVP approval

About this Event

The global pain market exceeds $87 billion, with opioids still accounting for $22 billion despite their well-known risks. Xgene Pharmaceutical, a clinical-stage biotech company, is developing non-opioid treatment alternatives that are safer and more effective than the current standard of care for both acute and chronic pain.

Xgene is utilizing its proprietary multimodal conjugate platform technology to link two therapeutic molecules into one dual-acting medication. Together the active ingredients reduce inflammatory cytokines and inhibit the transmission of pain signals, to provide highly effective non-opioid relief for both acute and chronic pain with minimal side effects.

The company’s oral lead candidate, XG005, recently completed a Phase 2 trial for post-surgical pain and a Phase 2 trial for chronic pain showing significant reductions in pain scores versus placebo. In the post-surgical study, 43% of patients required no rescue medication, and 74% avoided opioids entirely. Xgene is now preparing for two Phase 3 trials to continue evaluation of XG005 for the treatment of acute pain.

Beyond XG005, Xgene is advancing two additional programs: XG004, a topical dual-acting therapy for chronic pain and XG002 an oral single molecule candidate for neuropathic pain.

Please join our webinar with Xgene Head of Business Development, Iwona Beczkowska, Ph.D., to hear more about their robust pipeline of innovative, non-opioid therapeutics, and why Xgene is positioned to transform pain management for millions worldwide.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.